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INTRODUCTION 
 
 
 
This is a study of 50 cases of Solitary Pulmonary Lesion presented at 
Coimbatore Medical College Hospital, a tertiary care hospital in south 
India. The purpose of this study being to diagnose the different causes of 
Solitary Pulmonary Lesion with special emphasis on early detection of 
bronchogenic carcinoma. 
 
• A solitary pulmonary nodule (SPN) is a small, round or egg-shaped 
lesion in the lungs. SPNs are typically asymptomatic, and they are 
usually noticed by chance on a chest x-ray that has been done for 
another reason. They are usually less than 3 cm in diameter (no 
larger than 6 cm)1 and are always surrounded by normal, 
functioning lung tissue.  
• The finding of a Solitary Pulmonary Nodule on a chest x-ray is a 
diagnostic dilemma often faced by many clinicians. The 
differential diagnosis ranges from a broad group of benign, 
infective, inflammatory, vascular, traumatic, congenital and 
malignant causes2. In India, upto sixty percent of all SPNs could be 
benign2,5 due to high rate of infections30 specially TB. Malignant 
SPNs may be primary stage IA lung cancer or metastases3. Upto 
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30% of all bronchogenic carcinoma can present as SPN. Upto 88% 
of malignant SPNs in stage IA are resectable & hence 5 year 
survival rate is excellent, approaching 70-80%3,4. Unfortunately, 
approximately one half of all lung cancers have extrapulmonary 
spread at the time of diagnosis. As a result, the average patient with 
a diagnosis of lung cancer has a 5-year survival of only 10 to 15%5. 
Therefore, it is prudent that malignant form of SPN are promptly 
evaluated and managed. In general, all SPNs should be considered 
malignant until proven otherwise13.  
• A confirmed diagnosis of a benign lesion like infection, 
granulomata and benign lung tumour also obviates the need to 
undergo surgical resection of the lesion. Thus unnecessary 
exploratory thoracotomy with its attendant morbidity can be 
avoided. 
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AIM OF THE STUDY 
 
 
 
With worsening industrial pollution and rampant smoking habits, the 
incidence of bronchogenic carcinoma is rising menacingly. Till date the 
treatment is mostly palliative rather than curative, unless diagnosed early. 
Thus the objective of this study is -   
• To diagnose early cases of bronchogenic carcinoma who have 
excellent 5 year survival rate. 
• This study also focuses on diagnosing cases of tuberculosis, which 
are completely curable and aims to differentiate it from other 
infective, granulomatous and benign causes of Solitary Pulmonary 
Nodule. 
• To study the various clinical and pathological presentations of 
Solitary Pulmonary Nodule presented in this hospital. 
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REVIEW OF LITERATURE 
Background:  
A Solitary Pulmonary Nodule (SPN) is defined as a single discrete 
pulmonary opacity surrounded by normal lung tissue and is not associated 
with adenopathy or atelectasis. The differential diagnosis may be broad 
but implications rest on whether the lesion is benign or malignant.  
Radiographically, a nodule is defined as a lesion smaller than 3 cm1. 
Anything larger than 3 cm is termed a mass. 
Pathophysiology:  
Pathophysiology of pulmonary nodules depends on etiology. 
Frequency:  
SPNs are fairly common. Screening studies in adults reveal SPNs in 1-2 
per 1000 chest radiographs80. In the United States, an estimated 150,000 
SPNs are detected annually2. Overall, incidence of malignancy ranges 
from 10-70%2,6,7,8. The higher incidence is largely the result of a selection 
bias, depending on the population under study (e.g., age, smoking status, 
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referral pattern, and location of the study9). Indian scenario as assessed by 
various previous publications is similar. 
Mortality / Morbidity:  
Prognosis depends on whether the lesion is benign or malignant and the 
stage of the lung cancer on presentation.  
Following resection of a solitary bronchogenic carcinoma (stage IA), the 
5-year survival rate is approximately 70-80%53.  
Sex:  
No difference in incidence exists between males and females2,5.  
Age:  
Solitary nodules can occur at all age levels. Early on, they usually are 
secondary to a benign lesion. The risk of malignancy increases with age. 
Clinical Presentation:  
Most SPNs are asymptomatic. The goal of investigating an SPN is to 
differentiate a benign lesion from a malignant lesion as soon and as 
accurately as possible.  
Important features in the patient history include the following:  
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• Age - Risk of developing malignancy increases with age9  
o 3% Risk  at age 35-39 years  
o 15% risk  at age 40-49 years  
o 43% risk  at age 50-59 years  
o Greater than 50% risk  in patients older than 60 years 
• Smoking history9  
• Prior history of malignancy9  
• Occupational risk factors for malignancy - Exposure to asbestos, 
nickel, chromium, vinyl chloride, and polycyclic hydrocarbons  
• Previous history of tuberculosis or pulmonary mycosis  
Preferred Investigation:  
Chest radiograph usually is the initial examination. Most SPNs are 
discovered as an incidental finding. With recent introduction of low dose 
CT chest scans16,36 as a screening tool for lung cancer, more and more 
smaller nodules will be detected requiring evaluation. As more large-
scale studies become available, positron emission tomography (PET) and 
single-photon emission computed tomography (SPECT) will become 
important imaging tools. 
Limitations of Techniques:  
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Chest radiographs demonstrate poorer resolution than chest CT scans in 
determining degree of calcification or size. Visualisation of some nodules 
may be difficult because of superimposed structures causing 20-50% of 
missed diagnosis14,15,16,17,18,19.  
Chest CT scans are limited by its cost and the need for intravenous 
contrast, which carries a risk of an adverse reaction. CT is not as easily 
available and portable as chest radiographs.  
Nuclear medicine imaging (PET and SPECT scan) is considerably more 
expensive than a chest CT scan or MRI study. PET and SPECT are 
available in few places only in India. 
 
DIFFERENTIAL DIAGNOSIS 
 
Malignant lesions: 
Bronchogenic carcinoma - Small cell, Large cell, Adenocarcinoma, 
and Squamous cell 
Carcinoids 
Solitary metastases 
 
Benign lesions: 
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Benign neoplasms - Hamartomas, Lipomas and Fibromas 
Vascular lesions - Arteriovenous malformation 
Infectious granulomas - Tuberculosis, Atypical mycobacterial 
infection, Histoplasmosis, Coccidioidomycosis and Blastomycosis 
Other infections - Aspergilloma, Ascariasis,  Echinococcal cyst and 
Bacterial abscess 
Noninfectious granulomas - Rheumatoid arthritis, Wegener 
granulomatosis and Sarcoidosis 
Developmental lesions - Bronchogenic cyst 
Others conditions - Hematoma, Bronchiolitis obliterans-organising 
pneumonia, Pseudo-tumour, Pulmonary infarction, Rounded 
atelectasis and Mucoid impaction 
False Positives / Negatives - Some SPN mimickers include nipple 
shadows, soft tissue tumors, bone / rib shadows and pleural plaques  
 
RADIOGRAPH 
Often, SPNs are discovered first as incidental findings on chest 
radiographs. The first step is to determine whether the nodule is 
pulmonary or extra pulmonary. A lateral chest radiograph, fluoroscopy, 
or CT of the chest often helps determine the location of the nodule.  
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Usually, nodules are identifiable by the time they are 8-10 mm on chest 
radiographs. Occasionally, SPNs can be visualised at 5 mm in diameter. 
Chest radiographs can provide information regarding nodule size, growth 
rate, margin characteristics, and calcification pattern, which can aid in the 
assessment of benign versus malignant lesions.  
• Nodule size: Nodules greater than 3 cm in diameter are more likely 
to be malignant, while those less than 2 cm are more likely to be 
benign31. But size alone is of limited value. In individual patients, 
small nodules can be malignant and larger nodules can be benign.  
• Growth rate:  
o Comparison of previous chest radiographs of the patient 
allows assessment of the growth rate. The growth rate refers 
to the doubling time of a nodule, i.e., doubling in volume. 
On chest radiographs, a nodule appears as a 2-dimensional 
representation of a 3-dimensional structure. The volume of a 
sphere equals 4/3 πr3; therefore, a 26% increase in diameter 
on a chest radiograph represents one doubling in volume. 
For example, an increase from 1-1.3 cm equals one 
doubling. A 1-2 cm increase relates to an 8-fold increase in 
volume.  
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o Bronchogenic carcinomas usually have a doubling time of 
20-400 days24.  
o Doubling times shorter than 20-30 days are seen in 
infections, infarction, lymphoma, or fast-growing 
metastases23.  
o Doubling times greater than 400 days are typically 
benign20,21.  
o Absence of change in size of a nodule over 2 years is highly 
suggestive of a benign lesion.  
o Determination of size of small nodules is not without error. 
On chest radiographs, a 3-mm enlargement may be difficult 
to appreciate. The use of digitally enhanced films may allow 
more accurate measurement of size. 
          
The above picture depicts the effect of initial nodule size on perception of 
growth. Our eyes perceive the change of diameter better, rather than the 
increase in volume. The smaller nodule appears to grow more slowly than the 
larger one, even though both are doubling in volume at the same rate. 
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• Margin characteristics: Benign lesions tend to have well-
circumscribed smooth borders. Malignant nodules typically have 
irregular, lobulated, or spiculated (corona radiata) borders. Of the 
margin descriptions, the spiculated border is the most sensitive in 
predicting malignancy25,26; however, it is not unusual for a 
malignant lesion to have a smooth contour, specially 
metastasis25,26.  
• Calcification:  Calcification within a nodule is more likely to be 
seen in a benign nodule; however, approximately 10% of malignant 
nodules demonstrate calcification. In benign lesions, 5 patterns of 
calcification are seen commonly, including diffuse, central, 
laminar, concentric, and popcorn (chondroid) calcifications. The 
popcorn pattern typically is described in hamartomas. A stippled or 
eccentric pattern is seen most commonly in malignant lesions 19,28. 
CT scan allows a more accurate detection and assessment of the 
calcification pattern than plain film22. 
.CT SCAN 
CT thorax allows better assessment of nodules. The advantages of CT 
over plain film include the following:  
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• Better resolution: Nodules as small as 3-4 mm is detectable. 
Morphologic features of specific diagnosis are better visualised 
(eg, rounded atelectasis, arteriovenous malformations).  
• Areas that are difficult to assess on plain radiography are visualised 
better on CT, such as the lung apices, perihilar regions, and 
costophrenic angles27,28,29.  
• Multiple nodules can be detected on CT scans.  
• Malignancy can be staged using CT.  
• CT can help guide needle biopsy.  
CT densitometry  
CT densitometry measures the attenuation coefficients of a particular 
lesion to determine its density. The results are expressed in Hounsfield 
units (HU).  
CT densitometry allows for detection of occult calcification that may not 
be appreciated visually, even on high-resolution thin-section CT of the 
chest. The difficulties with this technique have been in determining the 
appropriate level of the attenuation coefficients used to classify a lesion 
with a high probability of being benign. One study25 looking at 91 
nodules known to be malignant or benign proposed a cutoff of greater 
than 164 HU for benign lesions. In another study26 of 85 nodules 
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classified as benign using 185 HU as a cutoff, 9% were found to be 
malignant at biopsy. Densitometry in this setting may provide useful 
information if used in context with other clinical and radiologic features.  
Densitometry also allows detection of fat within a nodule, which is a 
common feature of benign nodules, especially in hamartomas.  
Other features of CT include the following:  
• Contrast enhancement: Malignant nodules tend to have greater 
vascularity than benign nodules. Nodular enhancement of less than 
15 HU suggests that a lesion is benign, and enhancement of greater 
than 20 HU is more likely associated with malignancy (sensitivity 
98%, specificity 73%)33.  
• Feeding vessel sign: This sign may be seen in hematogenous or 
vascular causes of pulmonary nodules such as metastatic deposits 
or septic emboli.  
• Cavity wall thickness25,32: Cavitation can be seen in both malignant 
and benign nodules. While a thin-walled cavity is highly suggestive 
of a benign lesion (<1 mm), a thick-walled cavity usually is 
indeterminate and is present in both benign and malignant lesions. 
 
MRI 
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MRI provides better imaging for pleural, diaphragm, and chest wall 
disease than CT when staging lung cancer. MRI is comparable to CT in 
assessing mediastinal involvement28,29 and is less useful in assessing the 
lung parenchyma (especially assessing pulmonary nodules) because of 
poorer spatial resolution. Since MRI costs more and is less available, 
MRI use is reserved for tumors that are difficult to assess on CT (eg, 
Pancoast tumours). 
 
ULTRASOUND 
 Ultrasound has a limited role in the form of percutaneous biopsy of 
larger peripherally based lesions for evaluating a SPN. 
 
NUCLEAR MEDICINE 
Recently, nuclear medicine imaging has been studied for use in 
evaluation of SPNs. Positron emission tomography (PET) and single -
photon emission computed tomography (SPECT) imaging have been 
approved for use in the United States for evaluating pulmonary nodules.  
PET imaging  
Malignant cells have higher metabolic rate than normal cells; therefore, 
glucose uptake is higher. Thoracic PET imaging uses the isotope fluorine-
18 bound to a glucose analog to make fluorine-18-fluorodeoxyglucose 
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(FDG). Increased FDG uptake is seen in most malignant tumours and is 
the basis of the PET study used to differentiate malignant from benign 
nodules.  
FDG uptake can be quantified using the standardised uptake ratio (SUR) 
to normalise measurements for a patient's weight and injected dose of 
radioisotope. This allows comparison of uptake between different lesions 
and patients. SUR greater than 2.5 has been used by some34,35,36 as a 
marker of malignancy.  
An additional advantage of FDG-PET imaging is better detection of 
mediastinal metastases34, improving the staging of lung cancers.  
SPECT imaging  
SPECT scanners have the advantage of being more readily available than 
PET scanners. Depreotide is a somatostatin analog labeled with 
technetium Tc 99m, which has been shown to bind to somatostatin 
receptors expressed on non-small cell carcinomas.  
Use of SPECT scanning has not been evaluated in a larger series.  
Overall, both FDG-PET and SPECT imaging are promising noninvasive 
techniques for differentiating malignant lesions from benign lesions and 
aiding in the assessment of indeterminate lesions. 
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In a study of a small series of patients, depreotide uptake demonstrated a 
sensitivity and specificity of 93% and 88%, respectively, for 
malignancy38. 
False Positives/Negatives:  Limitations of FDG-PET imaging include the 
following:  
• False-positive findings can occur in other metabolically active 
conditions that produce pulmonary nodules, such as infectious 
granulomas or inflammatory lesions.  
• False-negative findings can be seen in the following:  
o Small tumours: The resolution of current PET scanners is 7-
8 mm; therefore, they may miss tumors smaller than 10 mm.  
o Tumours with low metabolic rates, such as carcinoid and 
bronchioalveolar cell carcinomas, may not be distinguishable 
from background uptake37.  
o High serum glucose concentrations compete in cells with 
FDG; therefore, uptake of the radioisotope is reduced. 
INVASIVE  INVESTIGATIONS 
 After clinical and radiologic assessment of an SPN, all patients can be 
divided into 1 of 3 groups as follows:  
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• Patients with benign lesions: Benign status is based on patient age, 
younger than 35 years without other risk factors, stability of the 
SPN over 2 years on chest radiograph, or a benign pattern on chest 
radiograph. These patients have a low likelihood for malignancy 
and should be followed with serial chest radiograph or CT every 3-
4 months for the first year and every 4-6 months in the second year.  
• Patients with malignant lesions: Malignant status occurs with 
clinical and radiologic features in patients who have a high 
likelihood for a malignant lesion that will progress to a 
thoracotomy for removal.  
• Patients with indeterminate lesions: Most patients fall into this 
category. As many as 75% of these patients have malignant 
nodules on further evaluation. 
Bronchoscopy and biopsy 
• Usefulness is limited in lesions smaller than 2.0 cm.  
• In lesions larger than 2.0 cm, the yield for malignancy varies from 
40-69%45,46,47,48,49.  
• Yield is higher for nodules located in the inner one third46 of the 
lung fields or in close approximation to a bronchus on CT scans. 
Percutaneous needle biopsy  
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• This technique can be performed under fluoroscopy or with CT 
guidance.  
• Needle aspiration can be performed using a 21-gauge needle or 
needle aspiration plus core biopsy can be performed using an 18-
gauge or 19-gauge needle (higher yield42 with greater risk for 
pneumothorax44 ).  
• Yield is highest for peripheral nodules.  
• Sensitivity and specificity for malignant lesions is 80-95% and 50-
88%, respectively39,40.  
• Sensitivity for a specific benign diagnosis (eg, granuloma, 
hamartoma) is 11-68%41.  
• Controversy exists concerning needle aspirations / biopsies with 
negative results (ie, without a specific benign diagnosis). The 
negative predictive value of transthoracic needle aspiration to 
exclude malignancy varies from 52-88%. Options such as 
observation, repeat biopsy, or thoracotomy depend on the pretest 
probability for malignancy and patient-related factors, such as 
comorbid illness that may preclude a thoracotomy. A thoracotomy 
is indicated in patients who still have a high likelihood of 
malignancy.  
• Using on-site cytologic analysis increases sensitivity of 
percutaneous biopsy43. The presence of a cytologist at the time of 
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biopsy aids in assuring the adequacy of specimens. This can both 
decrease complications by reducing unnecessary collection of 
additional samples and increase the yield by informing the 
radiologist of the need to obtain additional samples.  
• Complications44  
o Pneumothorax is seen in as many as 30% of these patients 
and approximately 5% require a chest tube.  
o Hemoptysis is seen in 5-10% of these patients and usually is 
minor and resolves spontaneously.  
o Fatal hemorrhage and air embolism are rare. 
• Contraindications  
o Limited pulmonary reserve (forced expiratory volume in 1st 
second <1.0 L)  
o Emphysema or blebs in the path of the needle  
o Coagulopathy  
o Inability to hold breath  
o Severe pulmonary hypertension  
o Contralateral pneumonectomy 
 Thoracoscopy or thoracotomy  
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• A thoracotomy and lobectomy with lymph node sampling is the 
treatment of choice for patients with stage IA bronchogenic 
carcinoma50,51,52,53.  
• In patients with an indeterminate nodule and a high probability of 
malignancy, a thoracotomy should be performed if the patient has 
adequate pulmonary reserve.  
• Recently, video-assisted thoracoscopy surgery (VATS) has been 
used for removal of peripheral nodules with a wedge resection52,54. 
If at the time of VATS the frozen section is positive for 
malignancy, an open thoracotomy55 can be performed for proper 
anatomic resection. If a benign lesion is found, the procedure saves 
the patient from the invasiveness of a full thoracotomy and 
lobectomy. 
Assesment of probability of malignancy9,10,11,12:  
• In determining the most effective strategy for investigating an SPN 
and treating the patient, developing an estimate of the probability 
that the nodule is malignant is important. Bayesian analysis uses 
likelihood ratios of malignancy for various clinical and radiological 
factors. The ratios are combined to produce a probability of 
malignancy (PCa). 
 26
• When the probability of malignancy is high (PCa >70%), a 
resection is warranted. Similarly, if the probability is low (PCa 
<5%), observation is recommended. For lesions with an 
indeterminate probability, further evaluation is necessary. 
• Calculation of probabilities provides only an estimate of 
malignancy and it cannot be generalised in respect of all patients.  
Probability of Malignancy in SPN: Bayesian Analysis10 
The main objective of Bayesian analysis is to use all the clinical 
and radiographic characteristics to derive a quantitative estimate of 
the probability that a SPN is malignant. 
This is a mathematical theorem after presentation of all data regarding 
the nodule (details below) to the java program which will calculate the 
probability of malignancy. The necessary facts are- 
• Prior Probability of Malignancy: 
• Clinical charecteristics: Age, Smoking (Pack-yrs), 
Haemoptysis,  History of  previous malignancy 
• Radiographic charecteristics: Size (in cm), Location, Edge, 
Growth rate, Cavity wall thickness, Calcification 
• Additional characteristics:  Contrast enhancement, PET 
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MATERIALS AND METHODS 
 
 
 
Period of Study: 
This study was done from January 2006 to August 2007. 
 
Setting: 
A single discrete pulmonary opacity surrounded by normal 
lung tissue and not associated with adenopathy / atelectasis 
in the chest x-ray in the following group of fifty adults was 
taken as the starting point of the study. In order to 
overcome observer bias, concurrence of four individual 
observers was taken as a pre-requisite to include the case 
in the study population. 
 
Study Population: 
a) Asymptomatic adults, who had undergone 
hospital run master health   check up 
programme; 
 
Likelihood Ratios 
20-29 yrs 0.05
30-39 yrs 0.24
40-49 yrs 0.94
50-59 yrs 1.90
60-69 yrs 2.64
Nonsmoker 0.15
< 30 pk-yrs 0.74
30-39 pk-yrs 2 
>40 pk-yrs 3.7 
Hemoptysis, 
absent 1 
Hemoptysis, 
present 5.08
No prev malig 1 
Prev Malig 4.95
0-1 cm 0.52
1.1 - 2.0 0.74
2.1 - 3.0 3.67
> 3.0 cm 5.23
upper/middle 1.22
Lower 0.66
Smooth 0.3 
Lobulated 0.74
Spiculated 5.54
Growth, not 
known 1 
Benign growth 
rate 0.01
Malignant 
growth rate 3.4 
Not cavitated 1 
< 4 mm 0.07
5 - 15 mm 0.72
> 16 mm 38 
Not calcified 2.2 
Benign 
calcification 0.01
Enhancement <
15 HU 0.04
Enhancement > 
15 HU 2.32
SUR < 2.5 0.06
SUR > 2.5 7.1 
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b)  Patients presented with chest symptoms  in medicine OPD; 
c) Individuals who presented themselves for unrelated 
complaints in different OPDs for whom a routine chest x-ray 
was called for. 
 
 
Inclusion criteria: 
Following x-ray findings, as described by John D. Minna and Charles S. 
Scoggin 66,71, were taken as criteria for inclusion:  
a) Cases presenting with solitary pulmonary parenchymal 
nodular lesion of 1- 6 cm in diameter.  
      b) The nodule appears to lie within the pulmonary parenchyma, 
with aerated lung tissue around it.  
c) The lesions are round or ovoid in shape.  
d) Patients may have associated minimal pneumonitis, 
atelectasis or regional lymphadenopathy.  
e) The lesions are solitary (in some cases satellite lesions may 
be present) with circumscribed margin.  
 
 
Exclusion criteria: 
Size of the nodule >6cm 
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Obvious hilar, mediastinal, diaphragmatic and chest wall masses  
Co-morbid conditions- 
Bleeding diathesis – as assessed by BT, CT, platelet count 
Pulmonary hypertension 
   Multiple bullous lesions 
Extremely sick / dyspnoeic patient 
Method: 
Detailed history with special reference to age; sex; smoking habit; 
exposure to TB / STD; occupational risk and exposure to asbestos, nickel, 
chromium, polycyclic hydrocarbon; previous history of TB / pulmonary 
mycosis, DM, immunosuppresive disease / drugs was obtained. 
 
A thorough clinical examination with special attention to respiratory 
system, para-neoplastic syndromes and signs of metastasis was done. All 
other systems, specially, GI tract, prostate, testis, kidney, thyroid and 
breast & pelvis in females were carefully examined for primary lesion. 
 
Investigations:  
 
Other than routine blood, urine, tuberculin test, the important 
investigations carried out are as follows- 
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• Sputum – Gram stain; AFB stain; fungal KOH stain; 
bacterial C/S; mycobacterium TB Culture- L-J medium or 
Liquid culture medium; fungal culture in sabourand agar 
medium; malignant cell examination  were done. 
 
• Chest x-ray – PA view mostly, with occasional lateral view 
and digital enhancing x-ray as needed- size of lesion, growth 
rate, margin characteristics, calcification pattern were looked 
into for assessment and differentiation between benign / 
infective / malignant lesions. 
 
• CT thorax – Better visualisation and appreciation of nodule / 
mass is possible in CT thorax. No. and size; calcification 
pattern; staging for malignancy; densitometry of lesion; 
contrast enhancement; wall thickness; positive vessel sign 
were noted for differentiation between benign / infective / 
malignant lesions. 
• CT guided percutaneous fine needle aspiration cytology / 
tru-cut needle biopsy – from peripheral lesions and 
histopathological examination of the same. 
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• Bronchoscopy – Broncho-alveolar lavage, brushing, 
bronchoscopic biopsy for centrally placed lesions were done 
with bronchoscopy. 
• Fine needle aspiration cytology / excision biopsy of palpable 
significant lymph nodes, if any were done. 
 
 
 
OBSERVATION AND RESULTS 
 
 
 
Analysis of 50 persons presenting with Solitary Pulmonary Nodule in 
chest x-ray presented at Coimbatore Medical College Hospital, who met 
the inclusion criteria was done. 
Total no. of chest x-ray screened – 4728. Incidence of SPN in this study 
is 1.26/ 1000 population. 
 
 
AGE and SEX DISTRIBUTION: (Table 1, Chart 1) 
 
Of the 50 persons in the study 48 (96%) were male and 02 (4%) were 
female. Mean age was 53.3 yrs with the range being 25 to 76 yrs. 
Majority (76%) of the persons were in age group 46-65 yrs. 
 
    
    Table 1:                                                                     Total cases - 50 
NUMBER OF 
CASES 
AGE GROUP 
(yrs) 
Male Female 
PERCENTAGE 25 – 35 2 0 4 
36 -  45 5 2 14 
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Chart 1:  AGE DISTRIBUTION OF CASES
 
 
 
 
 
DISTRIBUTION OF RISK FACTORS AMONG CASES:  
(Table 2, Chart 2) 
 
Cases had multiple risk factors. An overwhelming majority of the 50 
people studied were smoker, i.e. 41 persons (82%). Among the 41 
smokers, 9 cases were also exposed to industrial waste of toxic fumes of 
rubber & asbestos factory. Both the males having exposure to STD were 
also smoker. 5 of the diabetics were smoker. Both the women were type 2 
diabetic. 
46  -  55 20 0 40 
56 -   65 18 0 36 
66  -  76 3 0 6 
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Table 2:  Distribution of Risk factors 
 
RISK  FACTORS 
 
 
NO. OF PATIENTS PERCENTAGE 
Smoking 
 
41 82 
Exposure/past h/o PTB 
 
6 12 
STD exposure 
 
2 4 
Occupational exposure 9 18 
DM 
 
9 18 
Immunosuppresive Drugs 3 6 
 
No risk factor 
 
5 10 
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Chart 2: DISTRIBUTION OF RISK FACTORS
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ANALYSIS OF CLINICAL SYMPTOMS: (Table 3, Chart 3) 
 
A significant number of persons were chest asymtomatic i.e. 18 (36%). 
Commonest symptom was cough (20 persons, 40%); mostly dry cough 
(10 persons, 20%). Next commonest was vague ill health and weight loss 
(7 persons, 14%). Patients had multiple symptoms. 
Table 3: 
CLINICAL SYMPTOMS 
 
 
NO. OF CASES PERCENTAGE
Asymtomatic 
 
18 36 
Chest pain 
 
5 10 
Dry cough 10 20 
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Cough + Expeectoration 
 
6 12 
Cough + Dyspnoea 
 
2 4 
Cough + Haemoptysis 
 
2 4 
Ill – health 
 
6 12 
Loss of weight 
 
1 2 
 
 
 
ANALYSIS OF DURATION OF SYMPTOMS: (Table 4, Chart 4) 
 
Table  4          
DURATION (MONTHS) 
 
 
NO. OF CASES PERCENTAGE 
Asymptomatic 18 36 
0 – ½ 15 30 
½ - 1 8 16 
1 – 2 4 8 
2 – 3 2 4 
3 and above 3 6 
Other than the 18 (36%) asymptomatic cases, the interval between the 
onset of symptoms and seeking consultation was 15 days in 15 (30%) 
patients, ½- 1 month in 08 (16%) and 1–2 months in 4 (8%), suggesting 
that most patients seek relief from symptoms quite early. 
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Chart 4.  DISTRIBUTION OF SYMPTOM DURATION
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ANALYSIS OF PHYSICAL SIGNS: (Table 5, Chart 5) 
13 of them (26%) did not have any general examination or systemic 
examination finding. 5 patients each were having cervical 
lymphadenopathy and clubbing. Minimal lung findings like a few 
occasional crackles and wheeze were present in 25 persons (50%). 
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Table 5 
PHYSICAL SIGNS 
 
 
NO. OF CASES PERCENTAGE 
 
No sign 
 
13 26 
Cervical lymphadenopathy 
 
5 10 
Clubbing 
 
5 10 
Hepatomegaly 
 
1 2 
Skin nodule 
 
1 2 
Minimal lung signs 
 
25 50 
 
13,
26%
5 5
1 1
25,
50%
0
5
10
15
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25
No.
No Sign Cer. LN Clubbing Hepato
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Minimal
Lung
Finding
Chart 5.  PHYSICAL SIGNS
 
 
FEATURES OF NODULE IN X – RAY AND CT THORAX: 
 
 
DISTRIBUTION OF SOLITARY NODULE: (Table 6, Chart 6) 
 
Table 6                     Total cases- 50 
SITE 
 
 
NO. OF CASES PERCENTAGE 
Upper lobe       right 
                       left 
16 
13 
32 
26 
 39
 
              Middle lobe      right 
                       left 
 
2 
1 
4 
2 
Lower lobe      right 
                       left 
 
12 
6 
24 
12 
              Position            central 
                                   peripheral 
 
21 
29 
42 
58 
 
From the above table, it is evident that in more than half of the total cases 
(58%), the upper lobes were involved. The right side involvement was 
more i.e. in 30 out of 50 (60%) cases. Central lesions were 21 (42%), and 
peripheral lesions were 29 (58%).  
 
 
SIZE OF OPACITY IN CHEST X – RAY: (Table7, Chart 6)  
 
Table 7                                                                         Total cases- 50 
 
MARGIN OF OPACITY: (Table 8, Chart 6) 
 
Table 8                                                                                Total cases- 50 
MARGIN CHARACTERISTICS NO. OF CASES PERCENTAGE 
 
 
Smooth 
 
27 54 
Lobulated 
 
5 10 
Spiculated 
 
18 36 
SIZE IN CM. 
 
 
NO. OF CASES PERCENTAGE 
1.1 – 2 
 
2 4 
2.1 – 3 
 
9 18 
3.1 – 4 
 
14 28 
4.1 – 6 
 
25 50 
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THICKNESS OF CAVITY WALL IN NODULE: (Table 9, Chart 6) 
 
Table 9                                                                                 Total cases- 50 
THICKNESS OF CAVITY 
 
 
NO. OF CASES PERCENTAGE 
Non – cavitary 
 
44 88 
< 4 mm 
 
3 6 
4 – 15 mm 
 
2 4 
> 15 mm 
 
1 2 
 
 
CALCIFICATION OF NODULE: (Table 10, Chart 6) 
 
Table 10                                                                               Total cases- 50 
CALCIFICATION PATTERN 
 
 
NO. OF CASES PERCENTAGE 
No calcification 
 
40 80 
Benign pattern 
 
9 18 
Stippled / eccentric 
 
1 2 
 
 
CONTRAST ENHANCEMENT: (Table 11, Chart 6) 
Table 11                                                                               Total cases- 50 
CONTRAST ENHANCEMENT NO. OF CASES PERCENTAGE 
< 15 HU 18 36 
> 20 HU 32 64 
Chart 6:  FEATURES OF NODULE IN X – RAY AND CT THORAX 
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YIELD  OF  INVASIVE  DIAGNOSTIC  METHODS: 
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Transthoracic CT guided needle aspiration cytology / biopsy and 
bronchoscopy were performed in 40 cases where the diagnosis of 
malignancy was suggested by other diagnostic procedures and in those 
where other methods of diagnosis had failed or were of doubtful 
positivity. Transthoracic needle aspiration cytology / biopsy were done in 
22 cases; bronchoscopy was performed in 18 cases and cervical lymph 
node aspiration cytology/ biopsy in 5 cases. Bronchoscopy was preferred 
in central lesions whereas transthoracic approach was undertaken in 
peripheral lesions. Aspiration cytology/ biopsy were done in palpable 
significant cervical lymph nodes.  
 
A. Lymph node aspiration cytology/excision biopsy: (Table 12, Chart 7) 
 
The final diagnosis was established by lymph node aspiration cytology / 
excision biopsy in all the 5 cases of cervical lymph nodes with efficacy 
rate of 100%. Sizes of the lymph nodes were 2–3 cm. Excision biopsy 
were done in 2 cases and in other 3 cases fine needle aspiration cytology 
was diagnostic. In the 2 cases that had undergone excision biopsy, fine 
needle aspiration cytology taken prior to that was inconclusive. All 5 
cases proved to be malignant lesion, 3 were squamous cell carcinoma, 1 
was small cell carcinoma and 1 was metastatic carcinoma. 
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Table 12. Lymph node FNAC/excision biopsy                       Total no. 5 
RESULT 
 
 
NO. OF CASES PERCENTAGE 
Squmous cell carcinoma 3 60 
Small cell carcinoma 1 20 
Metastasis 1 20 
 
 
B. Transthoracic needle aspiration cytology / biopsy: (Table 13, Chart 7) 
 
Out of the 22 CT guided aspiration cytology / biopsy of lungs, 7 cases 
have undergone needle aspiration and rest 15 cases, tru–cut needle 
biopsy.  Malignant pathology was obtained in 11 (50%), inflammatory 
cytology in 4 (18%), tuberculosis in 3 (14%), and non-specific cytology 
in 2 (9%) cases. One each case of hamartoma and sarcoid nodule were 
also diagnosed. Among the cases of malignancy, 8 were adenocarcinoma, 
2 were squamous cell carcinoma and 1 was small cell carcinoma.  
 
Table 13                           Total no. - 22 
RESULT 
 
 
NO. OF CASES PERCENTAGE 
Malignancy 
 
Adenocarcinoma 
           Squmous cell carcinoma 
     Small cell carcinoma 
 
11 
 
8 
2 
1 
50 
 
36 
9 
4 
Inflammatory  cytology 
 
5 23 
Tuberculosis 
 
2 9 
Hamartoma 
 
1 4 
Sarcoidosis 
 
1 4 
Non – specific  cytology 
 
2 9 
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 C.  Fibre–optic Bronchoscopy: (Table 14, Chart 7) 
 
Out of the 18 cases undergone bronchoscopy, 7 cases had bronchial 
brushing and lavage; rest 11 cases had punch biopsy taken from 
bronchoscopically visualised lesions. Malignant pathology was obtained 
in 11 (61%) and tuberculosis in 3 (17%). One person had mucoid 
impaction. Non–specific cytology was reported in 2 (11%) cases. Among 
the cases of malignancy detected, 8 were squamous cell carcinoma, one 
each were small cell carcinoma and adenocarcinoma – alveolar cell type. 
One case of carcinoid was also detected.   
 
 
 
 
Table 14                           Total no. - 18 
RESULT 
 
 
NO. OF 
CASES 
PERCENTAGE 
Malignancy 
 
Squmous cell carcinoma 
              Adenocarcinoma 
              Small cell carcinoma 
              Carcinoid 
 
11 
 
8 
1 
1 
1 
61 
 
44 
5 
5 
5 
Tuberculosis 
 
3 17 
Mucoid impaction 
 
1 5 
Non – specific cytology 
 
3 17 
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EFFICACY OF VARIOUS DIAGNOSTIC PROCEDURES:  
(Table 15, Chart 8) 
The efficacy of diagnosis is slightly better in transthoracic aspiration 
cytology / biopsy (91%), than in fibre – optic bronchoscopy and lavage / 
brushing / biopsy (83%); though both of them are highly efficacious 
(above 80%).  
CT scan thorax was important to diagnose benign lesions and could 
diagnose pleural effusion in major fissure (pseudo –tumour), hamartoma 
and lung abscess. 
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TABLE 15.  Efficacy of various diagnostic procedures  
BASIS OF DIAGNOSIS 
 
 
NO. OF 
CASES 
EFFECTIVE
TOTAL 
NO. OF 
CASES 
PERCENTAGE
Sputum for AFB 
 
3 50 6 
Sputum for malignant cells 
 
2 50 4 
Sputum culture / sensitivity 
 
3 50 6 
Lymph node aspiration 
cytology / excision biopsy 
5 5 100 
Transthoracic aspiration 
cytology / biopsy 
20 22 91 
Fibre – optic bronchoscopy 
lavage / brushing / biopsy 
15 18 83 
CT scan with contrast 
     Pseudotumour 
Hamartoma 
  Lung abscess 
4 
2 
1 
1 
50 8 
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Chart 8:  EFFICACY OF VARIOUS DIAGNOSTIC 
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FINAL ETIOLOGICAL RESULT: (Table 16, Chart 9) 
 
Table 16                                                                                    Total no - 50 
DIAGNOSIS 
 
NO. OF 
CASES 
PERCENTAGE 
Malignancy 
 
           Squmous cell carcinoma 
Adeno carcinoma 
     Small cell carcinoma 
                     Carcinoid 
                     Metastasis 
 
27 
 
13 
9 
3 
1 
1 
 
54 
 
26 
18 
6 
2 
2 
 
Benign tumour – hamartoma 
 
1 2 
Pneumonia / abscess 
 
5 10 
Tuberculosis 
 
8 16 
Sarcoidosis 
 
1 2 
Pseudo –tumour 
 
2 4 
Mucoid impaction 
 
1 2 
No definite diagnosis 
 
5 (3) 10 (6) 
 
 
Out of the 5 cases (2 cases of transthoracic needle aspiration / biopsy; 
other 3 of bronchoscopic biopsy) of indefinite diagnosis of non–specific 
cytology, 2 cases were reasonably proved to be benign lesion. Both of 
them were 2 cm, smooth margin nodule, and were males in age group of 
36–45 yrs. Both these nodule sizes remained same over 1 year period of 
follow–up. Other 3 cases are on follow–up currently. 
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ASSOCIATION OF RISK AND PROBABILITY FACTORS WITH 
MALIGNANCY:  
 
A.  SMOKING : (Table 17, Chart 10) 
 
Table 17 
SMOKING 
(PACK – YRS) 
 
SOLITARY 
NODULE 
ANALYSED 
CASES OF 
MALIGNANCY 
PERCENTAGE 
YIELD 
Non – smoker 
 
9 2 22 
1 – 20 
 
10 3 30 
21 – 40 
 
15 9 60 
> 40 
 
16 13 81 
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B. AGE:  (Table 18, Chart 10) 
 
Table 18 
AGE GROUP 
(YRS.) 
SOLITARY 
NODULE 
ANALYSED 
 
CASES OF 
MALIGNANCY 
PERCENTAGE 
YIELD 
25 – 35 
 
2 1 50 
36 -  45 
 
7 1 `14 
46  -  55 
 
20 10 50 
56 -   65 
 
18 13 72 
66  -  76 
 
3 2 66 
 
 
C. SIZE OF NODULE: (Table 19, Chart 10) 
 
Table 19 
SIZE IN CM. 
 
 
SOLITARY 
NODULE 
ANALYSED 
CASES OF 
MALIGNANCY 
PERCENTAGE 
YIELD 
1.2 – 2 
 
2 0 0 
2.1 – 3 
 
9 2 22 
3.1 – 4 
 
14 7 50 
4.1 – 6 
 
25 18 72 
 
D. POSITION OF NODULE: (Table 20, Chart 10) 
 
Table 20 
POSITION SOLITARY 
NODULE 
ANALYSED 
CASES OF 
MALIGNANCY 
PERCENTAGE 
YIELD 
Upper + middle 
Lobe 
 
32 18 56 
Lower 
 
18 9 50 
Central 
 
21 11 52 
Peripheral 
 
29 16 55 
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E. MARGIN OF NODULE: (Table 21, Chart 10) 
 
Table 21 
MARGIN 
CHARECTERISTICS 
SOLITARY 
NODULE 
ANALYSED 
CASES OF 
MALIGNANCY 
PERCENTAGE 
YIELD 
 
Smooth 
 
27 9 33 
Lobulated 
 
5 1 20 
Spiculated 
 
18 17 94 
 
 
F. CALCIFICATION OF NODULE: (Table 22, Chart 10) 
 
Table 22 
CALCIFICATION 
PATTERN 
 
 
SOLITARY 
NODULE 
ANALYSED 
CASES OF 
MALIGNANCY 
PERCENTAGE 
YIELD 
No calcification 
 
40 26 65 
Benign pattern 
 
9 0 11 
Stippled / eccentric 
 
1 1 11 
 
 
G. CAVITARY WALL THICKNESS: (Table 23, Chart 10) 
 
Table 23 
THICKNESS 
OF  CAVITY WALL 
 
 
SOLITARY 
NODULE 
ANALYSED 
CASES OF 
MALIGNANCY 
PERCENTAGE 
YIELD 
Non – cavitary 
 
44 25 56 
< 4 mm 
 
3 0 0 
4 – 15 mm 
 
2 1 50 
> 15 mm 
 
1 1 100 
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H. CONTRAST ENHANCEMENT OF NODULE: (Table 24, Chart 10) 
 
Table 24 
CONTRAST 
ENHANCEMENT 
SOLITARY 
NODULE 
ANALYSED 
CASES OF 
MALIGNANCY 
PERCENTAGE 
YIELD 
< 15 HU 18 6 33 
> 20 HU 32 21 65 
 
 
These tables show maximum association of risk and probability factors 
with malignancy are as follows –  
Spiculated margin (94%), smoking > 40 pack–yrs (81 %), size >4 cm 
diameter (72%), age above 60 yrs (72%), contrast enhancement of > 20 
HU (65%), non–calcified (62%) and non-cavitary lesions (56). 
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A FEW SOLITARY PULMONARY NODULES FROM THE STUDY 
 
 
 
 
 
 
 
  
 
 
Solitary metastastatic tumour in a 45 year old man. 
Chest CT scan shows a smoothly marginated, 2-cm 
peripheral nodule. 
Squamous cell carcinoma in a 53 year old man. 
Chest CT scan of the right lung shows a lobulated 
and spiculated nodule in the lower lobe. 
Squamous cell carcinoma in a 55 year old man. 
Chest CT scan shows an irregular nodule above the 
major fissure. 
Squamous cell lung carcinoma in a 61 year old man. 
Close-up chest CT scan of the right lung shows a 
spiculated nodule with eccentric cavitation in the 
upper lobe. 
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A FEW SOLITARY PULMONARY NODULES FROM THE STUDY 
 
 
 
 
 
 
 
 
TB infection in a 45 year old woman with DM. 
Close-up chest CT scan of the right lung shows 
a thin-walled cavitary nodule. 
Squamous cell carcinoma in a 59 year old man. 
Close-up x-ray of the right lung shows a 
smoothly marginated nodule with eccentric 
cavitation and thick walls in the lower lobe. 
TB Granuloma in an asymptomatic 62 year old 
man. Close-up chest CT scan of the left lung 
shows a soft-tissue nodule with central 
calcification and eccentric cavitation in the 
upper lobe. 
AdenoCarcinoma lung  in a 65 
year old man. Close-up chest X-
ray of right lung shows a 
lobulated, sharply marginated 
nodule in the upper lobe. Also 
there is presence of emphysema 
and upper lobe bullae.  
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A FEW SOLITARY PULMONARY NODULES FROM THE STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Round pneumonia in a 37 year old woman who 
presented with cough and fever. Close-up X-ray of the 
left lung shows a poorly marginated nodule. Because of 
clinical symptoms, the patient was treated for 
community acquired pneumonia. Follow-up x-ray 
performed 2 weeks later showed complete resolution of 
the nodular opacity. 
Hamartoma in a 44 year old asymptomatic man. Chest CT scan right lung shows a 
lobulated nodule with central popcorn like calcification. Photomicrograph confirms the 
presence of adipose tissue (arrow) and epithelial tissue containing an island of basophilic 
cartilage (arrowhead). This mixture of epithelial and mesenchymal tissue is diagnostic. 
Carcinoid in a 61 year old man. CT thorax shows a 
lobulated lesion with scattered stippled 
Calcification of  
Left lower 
lobe. 
Smooth margined asymptomatic mass lesion in left 
lung – CT thorax proved Pseudo-tumour, Pleural 
effusion in transverse fissure. 
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A FEW SOLITARY PULMONARY NODULES FROM THE STUDY 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 25 yrs man with small cell carcinoma (post –radiotherapy photo); having (B) 
smooth margined 3 cm peripheral nodule with (C) rib erosion shown in CT 
thorax. (D) Post 3 cycle of radiotherapy x-ray shows disappearance of the nodule 
with persistence of rib erosion. (E) Photomicrograph shows characteristic sheet 
of malignant cells at centre with hyperchromatic nuclei folded upon itself with 
scanty cytoplasm. 
A B
C D
E 
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A FEW SOLITARY PULMONARY NODULES FROM THE STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) CT guided fine needle 
aspiration being done;  
(B) Showing procedural 
complication of minimal 
pneumothorax. 
A 
B 
(A) Bronchoscopic view of tiny overhanging mass of 
Squmous cell carcinoma;  
(B) Repeat bronchoscopy after 6 months of chemo and 
radiotherapy shows resolution of the lesion
A B
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DISCUSSION 
 
 
Bronchogenic carcinoma is one of the visceral malignancies, which gives 
an early roentgen clue to its existence, though it may be asymptomatic at 
that stage. In our geographic region high incidence of infections, 
especially tuberculosis, delays the early diagnosis and treatment of 
malignancy. In the present series, 50 cases of Solitary Pulmonary 
Nodules (SPN) in chest x–ray presented to Coimbatore Medical College 
Hospital from January 2006 to August 2007 were studied. 
 
Age and Sex: 
 
In this study the average age was 53.8 years, which is quite similar to 
other studies. Both infective and malignant causes rise with increasing 
age. It is now more common to come across cases of carcinoma of lung 
from fifth decade onwards with increasing environmental pollution and 
smoking habits66,74. In this study, significantly, the strength of association 
for malignancy is 72% for persons above 60 years of age with SPN.  
The youngest person in this study with Solitary Pulmonary Nodule is a 25 
year old male, non–smoker and is diagnosed with small cell carcinoma. 
He had only vague chest pain on presentation. He is presently doing well 
after 3 cycle chemotherapy and the post chemotherapy x–ray shows no 
evidence of the SPN, but minimal rib erosion which was present at the 
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beginning, persists. Thus the need for an early diagnosis cannot be more 
stressed upon.  
In this study, male patients were in overwhelming majority. Only 2 
female patients were present in age 35-45 years range, both were diabetic 
and were diagnosed as affected with infective etiology – one with TB 
another with consolidation / abscess. 
 
Risk Factors: 
 
A. Smoking: 
In this study, majority of the patients were smokers, i.e., 82%. Above 40 
pack–yrs, the risk of developing malignancy is very high, as reported in 
various studies58,59,62,63,64. This is also corroborated in our study with 81% 
SPN being malignant in smokers above 40 pack–yrs. This strength of 
association is only second to spiculated margin of the SPN (94%). 9 
(22%) of the smokers were also exposed to Occupational hazards. A 
comparative report of past Indian studies with our study is attached 
(Table 25). 
 
B. Other risk factors: 
9 (18%) of the SPNs were diabetic, 2 were HIV positive, 3 were having 
steroids for COPD and rheumatoid arthritis, 4 were old PTB cases. 
Majority i.e., 71% of this group had infective etiology of TB and 
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Pnuemonia / Abscess as their diagnosis. 5 (10%) cases did not have any 
apparent risk factor associated with. 
 
Symptoms: 
 
Symptoms, their presence or absence and their significance are difficult 
to evaluate in the patient having a solitary pulmonary nodule in x-ray 
chest. Most of the patients in the present study were asymptomatic or 
having vague ill-health (50%). Large majority had cough with / without 
expectoration (40%) and chest pain. It is comparable with previous 
studies of Arora et al95 and Jindal94 et al. The duration of symptoms 
before consultation was 15 days to one month in the majority of patients 
(52%). Thus presenting symptoms are rarely of help in establishing a 
diagnosis of solitary pulmonary lesion. Though haemoptysis, as reported 
by Gurney IW.10 have high degree of association with malignant SPN, in 
our study only 2 persons had presented with haemoptysis. One had TB, 
the other had malignant lesion. 
 
Signs:  
 
No clinching physical sign could be elicitable in this series of patients, 
with the possible exception of cervical lyphadenopathy noted in 5 (10%) 
cases. One of them had a cutaneous nodule present. Minimal lung 
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findings like a few occasional crackles and wheeze were present in half 
the cases (50%). In ¼ cases (25%), there were no elicitable signs. 
 
Features of nodule in x – ray and CT thorax: 
 
A. Margin and Size: 
The most important characteristic features of SPN have proved to be 
margin and size of the lesion66,69,70,73,74. In this study 18 (36%) of cases 
had spiculated margin, of which all but one case (94%) has turned out to 
be malignant. Sometimes only CT scan will reveal the spiculated nature 
of the margin in smaller lesions which deceptively may look as smooth 
margined in Chest x-ray70. Occurrence of malignancy in smooth 
margined lesions is also not rare as reported in many studies71,72,78. This 
study also confirmed this, i.e., 33% of smooth margined lesions were 
malignant.  
Larger the size of the lesion, it is more probable that the lesion is 
malignant. The probability doubles in lesions larger than 3 cm10,81,83. In 
this series, 50% of lesions of size 3–4 cm. and 72% of lesions of size 4–6 
cm. have turned out to be malignant. 
 
B. Location: 
In 64% of the cases, upper and middle lobes were involved. The right 
side involvement was more, i.e. in 30 out of 50 (60%) cases. Straighter 
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right bronchus and poor drainage of right middle lobe favours infective 
origin in right side lung. Central lesions were 21 (42%), and peripheral 
lesions were 29 (58%). Slightly higher number (56%) of malignancies 
has involved upper and middle lobes than the lower lobes (44%). There 
was no difference in incidence of malignancy found in peripheral (55%) 
and central lesions (52%). 
 
C. Calcification: 
There was evidence of calcification in 10 (20%) cases, 8 of which turned 
out to be tuberculous granulomas, 1 was hamartoma and only 1 case, in 
which there was stippled calcification, turned out to be malignant. Most 
radiologists agree that, it is not always possible to differentiate between 
benign and malignant nodules on the basis of size or margin 15,19,25,26,69,70. 
Lillington and Caskey24
 
reported that the presence of visible calcification 
is sufficient indication of benignity, but is not absolute proof, although 
the probability of cancer becomes very low.  
 
D. Thickness of cavitary wall and contrast enhancement: 
 
In this series, 56% of non–cavitary lesions were found to be malignant. 
There was only one case of thick walled cavity (> 15 mm), which was 
finally diagnosed as malignancy. Thin walled cavities, if present, usually 
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indicate infective / TB etiology. All 5 of the thin walled cavities within 
the nodule, in this study were non malignant. 
Contrast enhancement of the nodule in CT thorax of > 20 HU is an 
important indicator for higher probability of malignancy10. Infective 
conditions with increased vascularity also causes contrast enhancement. 
In this study, 65% of the contrast enhancing lesions were found to be 
malignant.  
 
E. Growth rate: 
Comparison of previous chest radiographs of the patient allows 
assessment of the growth rate. Malignant growth rate with doubling time 
of 20–400 days is very important indicator for higher probability of 
malignancy10,11,12. In this series, for 5 patients of SPN of 2 cm smooth 
margined nodule, no definite diagnosis could be arrived at after trans - 
thoracic needle aspiration and bronchoscopic biopsy due to non–specific 
cytology. Over one year of follow–up, the nodule sizes had not increased. 
This was sufficient to indicate pathology of benign origin.  
 
Yield of diagnostic methods: 
 
A. Fine needle aspiration cytology / biopsy of lymph node 
Fine needle aspiration cytology and excision biopsy plays a prominent 
role for tissue diagnosis, if any palpable cervical or axillary lymph node 
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is available. In this study, it was proved convincingly by having 
diagnosed 5 cases of malignancy out of the same number of cervical 
lymph nodes biopsied. Yield of excision biopsy is better than fine needle 
aspiration cytology. Fine needle aspiration cytology was inconclusive in 2 
cases, which were definitely proven malignant after excision biopsy done 
immediately later. The cases were as follows - 3 Squamous Cell 
Carcinoma, 1 Small Cell Carcinoma and 1 Metastatic Carcinoma. 
 
B. Transthoracic CT guided aspiration cytology / biopsy      
VS       
Fibre–optic Bronchoscopy and lavage / brushing / biopsy 
 
 
The efficacy of diagnosis is slightly better with transthoracic aspiration 
cytology / biopsy (91%), than with fibre–optic bronchoscopy and lavage / 
brushing / biopsy (83%). However, both of them are highly efficacious 
(above 80%) in properly selected patients.  
Transthoracic approach is favoured in peripheral lesions whereas for 
central lesions bronchoscopy is more favoured. This is because; only upto 
fourth order of bronchial divisions could be entered via fibre-optic 
bronchoscopy (Kovant et al84). Another drawback of usage of 
bronchoscopy is only in intra – bronchial pathology, biopsy or bronchial 
brushing / lavage under direct vision will be helpful. Only large lesions 
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are expected to be affecting the bronchial mucosa sufficiently for the 
biopsy or lavage to be diagnostic. When the lesion is < 2 cm, the yield is 
20-40%, but increases to 60-80% when the lesion is > 3 cm77. Kavale et 
al85 reported increased yield in non – visualised lesions when trans – 
bronchial lung biopsy is done under fluoroscopic guidance. Also Cortese 
et al79 reported that the diagnostic yield decreases when lesion is less than 
1.5 cm from the hilum. In this series of patients also, bronchoscopy was 
slightly less efficacious. All the patients selected for bronchoscopy were 
having larger lesions of > 3 cm and occupying central 1/3 of the lungs in 
X- ray. This result of 83% positivity is comparable to earlier Indian 
Studies where positivity results range from 45 – 88 %. As central lesions 
were more focused here, 44% cases of SPN, who underwent 
bronchoscopy were detected to have squamous cell carcinoma. 
CT guided FNAC of lungs has been increasingly used in recent years, 
because of its accuracy, safety, quickness and cost effectiveness. The 
diagnostic yield by percutaneous needle biopsy was 91%, of which 50% 
were malignant. This also compares well with literature where the yield 
has ranged between 50 – 96%65,67,68. The yield depends on size and 
position of the lesion. If the lesion is < 2cm, yield is 85%, for 2- 6 cm 
96%, but in lesion > 6 cm, it is reduced to 78% (Henschke et al82). The 
yield in smaller lesion is essentially good because of less secondary 
inflammation. In larger lesions, there is necrosis, which hampers correct 
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tissue diagnosis. The cutting needle tru cut biopsy is more useful than 
fine needle aspiration cytology in benign lesions and in metastatic tumour 
(Henschke et al82). This is because specimen obtained for 
histopathological study is better. But benign lesions like cysts and 
abscesses can only be diagnosed by fine needle aspiration cytology. As 
peripheral lesions are more important here, 36% of SPN, who underwent 
transthoracic aspiration / biopsy were found to be adenocarcinoma. 
Percutaneous needle biopsy was associated in all series with significant 
evidence of pneumothorax of 10 – 44%65. In this study it was 6% with 
none requiring chest tube drainage. 
 
Final etiological diagnosis: 
 
54% of cases i.e. 27 of the SPNs were found to be malignant in this study. 
The incidence of Malignancy found in this study was slightly higher than 
the average reported in earlier Indian studies 87,88,89,90,91,92,93,94,95,96,97,98,99. 
Out of the malignancies, squamous cell carcinomas were of 48% (13 in 
no.) whereas adenocarcinoma was of 33% (9 in no.) only. The higher 
incidence of squamous cell carcinoma is probably due to inordinately 
high number of heavy smokers (82%) in the study population and in India 
squamous cell carcinoma incidence is higher as reported in earlier 
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referred Indian studies. 11% (3 in no.) were small cell carcinoma, and 1 
each was carcinoid, metastatic lesion and benign tumour of hamartoma.  
26% of total cases of SPNs were of infective origin, of which 16% were 
TB and 10% were Pnumonia / Lung Abscess. 2 cases of Pseudo – tumour 
of fluid in transverse fissure were detected. There was one case of 
sarcoidosis and another case of mucoid impaction, which cleared after 
bronchoscopic lavage.  
Out of 5 cases of non – specific cytology, 2 cases were reasonably proved 
to be benign lesion. Both of them  were males in the age group of 36 – 45 
yrs, who had 2 cm smooth margined nodule, and both these nodules  
remained same over 1 year period of follow –up. Other 3 cases are on 
follow – up currently. 
 
 Prognosis of Malignancies in present study: 
 
Out of the 27 cases of malignancies presented as SPN, 5 (18%) cases 
were already having cervical lymphadenopathy, i.e. stage III B disease 
with reported poor prognosis of 5 year survival rate <5%58,62,63. 1 case 
(4%) of small cell carcinoma was having liver metastasis on presentation. 
This stage IV disease has reported 5 year survival rate of <1%58,62,63. One 
of the stage III B disease and the patient in stage IV at diagnosis has died 
within one year of diagnosis. 
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Among the remaining 21 cases, only 2 (7%) cases were in stage I A 
disease (with 5 year survival rate of 70-80%58,62,63), one was small cell 
carcinoma and another was adenocarcinoma. Both of them were 
peripheral lesion. Being diagnosed early, with treatment, both of them are 
faring well. Another 4 (15%) cases were in stage I B disease bearing good 
prognosis (5 year survival rate of 57%58,62,63). Rest 17 (62%) cases were 
stage II and III A diseases, with intermediately poor prognosis (5 year 
survival rate of 25 – 50%58,62,63). 
In this study only 22% of cases could be diagnosed sufficiently early to 
have good 5 year survival rate with treatment. Most of the cases of 
malignancy (88%) even in state of Solitary Pulmonary Nodule were 
detected only in fairly advanced stages. This is in accordance with other 
previous studies. This is for reasons noted below58,62,63- 
 - Signs and symptoms are inconclusive 
 - Significant number remain asymptomatic in early stage 
  -Nature of bronchogenic carcinoma being highly 
malignant with local and distant lymph node spread 
and metastasis happening much early in disease 
process. 
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SUMMARY 
 
 
 
• 54% of Solitary Pulmonary Nodule in the study was malignant.  
26% cases were of infective origin – tuberculosis and pneumonia / 
lung abscess. 14% cases were benign and 6% were indeterminate 
lesion. 
• 48% of the malignancies were squamous cell carcinoma, 33% were 
adenocarcinoma and 10% were small cell carcinoma.  
• Commonest malignancy in SPN was squamous cell carcinoma. 
Inordinately high number of smokers in study population probably 
predisposed to higher incidence of squamous cell carcinoma. 
• Symptoms and signs were not conclusive. 50% cases were 
asymptomatic or had vague ill-health. 40% had cough with or 
without sputum. Minimal non-specific lung signs (50%) or no 
elicitable physical sign (25%) were predominant findings.  
• 22% cases only could be diagnosed early enough for a favourable 
treatment response. 
• Exclusively males were found to have malignancy in SPN, though 
female sample size was very low (no. 2) in this study. 
• 72% of SPNs above 60 yrs of age were malignant. But even at age 
25 yrs, Small Cell Carcinoma has developed. 
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• 82% of study population were smokers, 81% of > 40 pack yrs 
smokers had developed malignancy.  
• 18% of SPNs were diabetics and were mostly having infective 
pathology. 
• Most important characteristic feature of SPN is margin and size of 
the lesion in x – ray. 
• 94% of spiculated margin and 72% of size >4 cm diameter nodules 
were malignant. 88% of <3cm nodules were benign/infective origin 
• 65% of nodules with contrast enhancement of > 20 HU in CT were 
malignant. 
• 2 cases of indeterminate pathology could be diagnosed of benign 
pathology only on basis of benign pattern of doubling time. 
• Both transthoracic aspiration cytology / biopsy and fibre – optic 
bronchoscopy and lavage / brushing / biopsy were important 
diagnostic tools in carefully selected patients with yield of > 80%. 
Overall, transthoracic aspiration cytology / biopsy were slightly 
more efficacious as a diagnostic measure.  
• Fine needle aspiration cytology / biopsy of lymph nodes were 
conclusive in palpable lymph nodes. 
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CONCLUSION 
 
 
 
The approach to a patient with a pulmonary nodule should be based on an 
estimate of the probability of cancer, determined according to the size of 
the nodule, the presence or absence of a history of smoking, the patient’s 
age, and characteristics of the nodule’s margins and contrast enhancement 
on CT imaging. 
As 54% of the Solitary pulmonary Nodules (SPN) was malignant in this 
study, high index of suspicion is the key to early diagnosis in view of 
inconclusive symptoms and signs. 
Low probability of cancer nodules need to be periodically reviewed; 
whereas possible malignant and indeterminate nodules need to be further 
investigated. 
Transthoracic CT guided fine needle aspiration/biopsy was slightly 
superior tool than bronchoscopy and biopsy for diagnosis. Fine needle 
aspiration/biopsy of significant palpable lymph nodes was very effective 
too.  
Though early diagnosis of malignancy in SPN was a goal, only 22% 
could be diagnosed early enough for a favourable treatment response, 
suggesting prevention by smoking recession is very important. 
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PROFORMA 
 
 
CLINICAL STUDY 
 
SOLITARY PULMONARY NODULE 
 
 
1. Serial No.: 
2. Patient’s Name:     Age:  Sex: 
3.   I.P. No.:  Ward:   DOA: 
4.   Address: 
5.  Occupation:      Income: 
6. Educational Standard: 
 
 
CHIEF COMPLAINTS: 
 
 
 
HISTORY OF PRESENTING ILLNESS: 
 
 
1. Cough                       Duration   
2.  Expectoration if any          Nature 
3.  Chest Pain   Duration   
4.  Dyspnoea    Duration 
5.  Haemoptysis   Duration   
6.  Fever    Duration 
7.  Generalised. ill-health    Duration          
8.  Weight Loss   Duration 
9.  Dysphagia        
10.  Hoarseness of voice 
11.  Pain Abdomen    
12.  Headache      13. Backache 
14.  Any other complaints 
 
 
RISK FACTORS:  
 
1. Smoking -   Pack-yrs 
2. DM 
3. Occupational exposure 
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4. Exposure to TB / STD 
5. Immuno-suppresive conditions 
 
 
HISTORY OF PAST ILLNESS: 
 
 
EXAMINATION: 
 
General Examination: 
 
 
Respiratory system: 
 
 
Abdomen: 
 
 
Other systems: 
 
 
Sign of Para-neoplastic syndrome: 
 
 
INVESTIGATIONS: 
1. Routine: 
 
Haemogram 
 
Blood Sugar    Urea   Creatinine 
 
Urine RE 
 
Tuberculin Test 
 
2. Sputum Examination: 
 
Gram stain 
AFB stain 
Fungal KOH stain 
Bacterial C/S 
Malignant cell 
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3. Chest Xray PA/ lateral/ digitally enhanced x-ray:  Nodule 
 
Site 
Size 
Margin Charecteristics 
Calcification 
Growth rate 
Any other finding 
 
4. CT Thorax:  Nodule 
 
Site 
Size 
Margin Charecteristics 
Calcification 
Growth rate 
Densitometry 
Contrast enhancement 
Feeding vessel sign 
Thickness of cavitary wall if any 
 
5. Trans-thoracic CT guided needle aspiration / biopsy 
 
Histo-pathological report 
Any complication of procedure 
 
6. Fibre-optic Bronchoscopy and lavage / brushing / biopsy  
 
Histo-pathological report 
Any complication of procedure 
 
7. Lymph node aspiration cytology/excision biopsy 
 
Histo-pathological report 
 
 
 
FINAL DIAGNOSIS:  
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ABBREVIATIONS 
 
 
Lt. – Left 
 
Rt. – Right 
 
UL – Upper lobe 
 
ML – Middle lobe 
 
LL – Lower lobe 
 
CEN – Cetral 
 
PER – Peripheral 
 
Occu. – Occupational 
 
Immuno Rx. – Immuno-suppresive drugs 
 
NA – Not applicable 
 
Min. – Minimal 
 
LN – Lymph node 
 
TTNA – Trans-thoracic needle aspiration 
 
   Comparative report of other Indian studies with present study90,91,92,93, 94,95,96,97,98 
 
S
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D
Y
9
0
,
9
1
,
9
2
,
9
3
,
9
4
,
9
5
, 
Author Total cases
M:F 
ratio 
Avg. 
age 
Smoker: 
Non-
smoker 
Squamous 
cell Ca 
(%) 
Large 
cell 
Ca 
(%) 
Adeno 
Ca 
(%) 
Small 
cell 
Ca 
(%) 
Unclassified
(%) 
Viswanathan et al 95    50.5  28.4  21.1 
          
Shankar et al 20 All M 54 5.7 73.3  20 6.7  
          
Nagrath et al 35 4 47.7 1.9 25.7  34.3  40 
          
Jha et al 25 2.9 46.6 5.3 44  20 20 20 
          
Narang et al 58 8.7 51.3 4.8 37.9  10.4 51.8  
          
Malhotra et al 70 7.8 49.6 4.8 50 7 14.3 13.7 17.1 
          
Jindal et al 1009 4.5 54.3 2.7 34.3 7.3 25.9 26.3 12.2 
          
Arora et al 100 4.6 50 1.5 27 10 21 1 3 
          
Sahu et al 25 11.5:1 59.3 4.1 50  25 8.3 8 
          
PRESENT 
STUDY 
50 24.1 53.8 6.8 48  33 11 8 
1 40453 53 MALE SQUAMOUS CELL CA 21-40 OCCU. EXP ASYMPTOMATIC N A CLUBBING
2 40632 52 MALE TB >40 IMMUN RX DRY COUGH  1-2 MIN. LUNG SIGN
3 40672 47 MALE ADENOCARCINOMA  1-20 OCCU. EXP ASYMPTOMATIC N A NO SIGN
4 40709 69 MALE SQUAMOUS CELL CA >40 NIL CHEST PAIN 0-0.5 CERVICAL LN
5 40777 53 MALE SQUAMOUS CELL CA 21-40 NIL ILL HEALTH  1-2 NO SIGN
6 40823 25 MALE SMALL CELL CA NON-SMOKER NIL CHEST PAIN  1-2 NO SIGN
7 40845 48 MALE TB  1-20 STD HAEMOPTYSIS 0-0.5 MIN. LUNG SIGN
8 40891 37 FEMALE ROUND PNEUMONIA NON-SMOKER DM DRY COUGH 0-0.5 MIN. LUNG SIGN
9 40919 45 MALE METASTASIS >40 OCCU. EXP CHEST PAIN 0.5-1 CERVICAL LN
10 40953 47 MALE PNEUMONIA/ABSCESS  1-20 STD DRY COUGH 0-0.5 MIN. LUNG SIGN
11 40978 52 MALE SQUAMOUS CELL CA 21-40 NIL ASYMPTOMATIC N A NO SIGN
12 40995 65 MALE SQUAMOUS CELL CA >40 OCCU. EXP ILL HEALTH  2-3 CERVICAL LN
13 41032 55 MALE PNEUMONIA/ABSCESS  1-20 DM DRY COUGH 0-0.5 MIN. LUNG SIGN
14 41058 65 MALE MUCOID IMPACTION >40 IMMUN RX EXPECTORATION 0-0.5 MIN. LUNG SIGN
15 41079 48 MALE ADENOCARCINOMA  1-20 NIL ASYMPTOMATIC N A NO SIGN
16 41082 58 MALE PNEUMONIA/ABSCESS  1-20 DM DRY COUGH 0-0.5 MIN. LUNG SIGN
17 41110 66 MALE TB 21-40 OCCU. EXP DRY COUGH 0.5-1 MIN. LUNG SIGN
18 41141 55 MALE SQUAMOUS CELL CA >40 DM CHEST PAIN 0.5-1 CLUBBING
19 41167 54 MALE SQUAMOUS CELL CA >40 NIL ILL HEALTH  2-3 NO SIGN
20 41275 49 MALE PSEUDO-TUMOUR  1-20 DM ASYMPTOMATIC N A MIN. LUNG SIGN
21 41313 45 FEMALE TB NON-SMOKER DM EXPECTORATION 0-0.5 MIN. LUNG SIGN
22 41497 56 MALE ADENOCARCINOMA 21-40 NIL ASYMPTOMATIC N A NO SIGN
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23 41620 44 MALE HAMARTOMA 21-40 NIL ASYMPTOMATIC N A NO SIGN
24 41771 51 MALE PSEUDO-TUMOUR 21-40 TB ASYMPTOMATIC N A NO SIGN
25 41811 63 MALE SQUAMOUS CELL CA 21-40 DM ASYMPTOMATIC N A CLUBBING
26 41950 77 MALE SQUAMOUS CELL CA >40 NIL DRY COUGH 0.5-1 SKIN NODULE
27 41973 40 MALE NO DEFINITE DX  1-20 IMMUN RX ASYMPTOMATIC N A NO SIGN
28 42068 47 MALE SARCOIDOSIS NON-SMOKER NIL DYSPNOEA 0.5-1 MIN. LUNG SIGN
29 42195 56 MALE ADENOCARCINOMA 21-40 NIL ASYMPTOMATIC N A MIN. LUNG SIGN
30 42236 61 MALE CARCINOID 21-40 NIL CHEST PAIN 0.5-1 NO SIGN
31 42250 36 MALE NO DEFINITE DX NON-SMOKER TB ASYMPTOMATIC N A NO SIGN
32 42410 56 MALE ADENOCARCINOMA  1-20 NIL ASYMPTOMATIC N A MIN. LUNG SIGN
33 42539 59 MALE SQUAMOUS CELL CA >40 NIL DYSPNOEA 0.5-1 MIN. LUNG SIGN
34 42789 48 MALE TB NON-SMOKER NIL EXPECTORATION 0-0.5 MIN. LUNG SIGN
35 42886 65 MALE SQUAMOUS CELL CA >40 NIL ILL HEALTH >3 CLUBBING
36 43108 65 MALE ADENOCARCINOMA >40 NIL ILL HEALTH >3 CLUBBING
37 43222 32 MALE PNEUMONIA/ABSCESS NON-SMOKER DM EXPECTORATION 0-0.5 MIN. LUNG SIGN
38 46701 62 MALE TB GRANULOMA 21-40 TB ASYMPTOMATIC N A MIN. LUNG SIGN
39 46993 64 MALE TB 21-40 TB EXPECTORATION 0-0.5 MIN. LUNG SIGN
40 47456 48 MALE ADENOCARCINOMA NON-SMOKER NIL ASYMPTOMATIC N A NO SIGN
41 47752 59 MALE TB GRANULOMA >40 OCCU. EXP EXPECTORATION 0-0.5 MIN. LUNG SIGN
42 50123 59 MALE SQUAMOUS CELL CA >40 NIL DRY COUGH 0.5-1 MIN. LUNG SIGN
43 50224 64 MALE SMALL CELL CA >40 OCCU. EXP HAEMOPTYSIS 0-.0.5 CERVICAL LN
44 52673 48 MALE ADENOCARCINOMA 21-40 NIL ASYMPTOMATIC N A NO SIGN
45 58752 60 MALE SMALL CELL CA >40 NIL DRY COUGH 0-0.5 HEPATOMEGALY
46 60539 55 MALE NO DEFINITE DX  1-20 DM ILL HEALTH >3 NO SIGN
47 60972 52 MALE NO DEFINITE DX NON-SMOKER NIL ASYMPTOMATIC N A NO SIGN
48 61949 48 MALE ADENOCARCINOMA 21-40 NIL ASYMPTOMATIC N A MIN. LUNG SIGN
49 62432 61 MALE SQUAMOUS CELL CA >40 OCCU. EXP WT. LOSS  1-2 CERVICAL LN
50 64659 44 MALE NO DEFINITE DX 21-40 OCCU. EXP DRY COUGH 0-0.5 NO SIGN
SITE SIZE(CM) MARGIN
THICKNESS 
OF CAVITY 
WALL(MM)
CALCIFICA
TION
CONTRAST 
ENHANCEM
ENT
LT.UL, CEN 5 SMOOTH NON CAVITARY NIL >20 HU 8400 HIGH 128
MALIG. 
CELL + BRONCHOSCOPY BIOPSY
RT.UL, CEN 2.8 SMOOTH NON CAVITARY BENIGN >20 HU 13000 LOW 146 BRONCHOSCOPY LAVAGE
RT.LL, PER 5 SPICULATED NON CAVITARY NIL >20 HU 1250 HIGH 138 TTNA/BIOPSY
RT.UL, PER 5 SPICULATED NON CAVITARY NIL <15HU 8600 HIGH 102 CER.LN.FNAC/BIOPSY
RT.UL, CEN 4.5 SPICULATED NON CAVITARY NIL >20 HU 8600
MODER
ATE 146 BRONCHOSCOPY BIOPSY
LT.ML, PER 4 SMOOTH NON CAVITARY NIL >20 HU 6300 HIGH 122 TTNA/BIOPSY
LT.UL, CEN 2.7 SMOOTH <4 BENIGN >20 HU 8100 HIGH 134 BRONCHOSCOPY LAVAGE
LT.UL, PER 2 SPICULATED NON CAVITARY NIL >20 HU 12000 HIGH 194 C/S + TTNA
LT.LL, PER 2.1 SMOOTH NON CAVITARY NIL <15HU 8000 LOW 152 CER. LN. FNAC/BIOPSY
LT.UL, PER 4 SMOOTH NON CAVITARY NIL >20 HU 9960 HIGH 110 C/S + TTNA
LT.UL, CEN 5 SPICULATED NON CAVITARY NIL >20 HU 6680 HIGH 104 BRONCHOSCOPY BIOPSY
RT.LL, PER 5 SPICULATED NON CAVITARY NIL >20 HU 11700
MODER
ATE 120 CER. LN.FNAC/BIOPSY
LT.UL, PER 2.3 SMOOTH NON CAVITARY NIL >20 HU 10200 HIGH 268 TTNA
RT.LL, CEN 6 SMOOTH NON CAVITARY NIL <15 HU 8200 LOW 104 BRONCHOSCOPY LAVAGE 
RT.LL, PER 4.5 NON CAVITARY NIL >20 HU 6000 HIGH 127 TTNA/BIOPSY
LT.UL, PER 4 SMOOTH NON CAVITARY NIL >20HU 8320 LOW 242 TTNA
RT.UL, CEN 2.6 SMOOTH <4 BENIGN >20 HU 6490 MODERATE 106 BRONCHOSCOPIC LAVAGE
LT.UL, PER 6 SPICULATED NON CAVITARY NIL >20 HU 14000
MODER
ATE 202 TTNA/BIOPSY
RT.UL, CEN 5 SPICULATED NON CAVITARY NIL <15HU 6800
MODER
ATE 110 BRONCHOSCOPY BIOPSY
LT.UL, CEN 6 SMOOTH NON CAVITARY NIL <15 HU 11100 LOW 238 NIL
RT.UL, PER 3 SMOOTH  4-15 BENIGN <15 HU 9240 HIGH 372 SPUTUM AFB + NIL
RT.UL, PER 6 SPICULATED NON CAVITARY NIL >20 HU 6800 HIGH 125 TTNA/BIOPSY
INVASIVE                
INVESTIGATIONESR SPUTUM
WBC 
COUNT
                                         CHARECTERISTICS OF NODULE
BLOOD 
SUGAR 
(PP)
RT.ML, PER 5 SMOOTH NON CAVITARY BENIGN >20 HU 8200 HIGH 140 TTNA/BIOPSY
LT.LL, CEN 2.9 SMOOTH NON CAVITARY NIL >20 HU 9600
MODER
ATE 122 NIL
LT.UL, CEN 6 SMOOTH NON CAVITARY NIL >20 HU 14000 LOW 222
MALIG. 
CELL + BRONCHOSCOPY BIOPSY
RT.UL, CEN 3.9 SPICULATED NON CAVITARY NIL >20 HU 9700 HIGH 104 BRONCHOSCOPY BIOPSY
RT.LL, PER 4 SMOOTH NON CAVITARY NIL <15 HU 8700 LOW 111 TTNNA/BIOPSY
RT. LL, PER 4 SMOOTH NON CAVITARY BENIGN <15 HU 4600 HIGH 130 TTNA/BIOPSY
RT.UL, PER 5 SPICULATED NON CAVITARY NIL >20 HU 8500 HIGH 132 TTNA/BIOPSY
LT.LL, CEN 4 LOBULATED NON CAVITARY STIPPLED <15 HU 11200 LOW 137 BRONCHOSCOPY BIOPSY
LT.LL, CEN 4 SMOOTH NON CAVITARY NIL <15 HU 9600
MODER
ATE 110 BRONCHOSCOPY LAVAGE
RT.UL, PER 5 SMOOTH NON CAVITARY NIL >20 HU 12000 HIGH 108 TTNA/BIOPSY
RT.UL, CEN 3.9 SPICULATED NON CAVITARY NIL >20 HU 9400 HIGH 120 BRONCHOSCOPY BIOPSY
RT.LL, CEN 6 SMOOTH <4 BENIGN <15 HU 7600 LOW 122 SPUTUM AFB + NIL
RT.LL, CEN 5 SPICULATED NON CAVITARY NIL >20 HU 9000 HIGH 130 BRONCHOSCOPY BIOPSY
RT.UL, PER 4 LOBULATED NON CAVITARY NIL >20 HU 8100 LOW 106 TTNA/BIOPSY
RT.LL, PER 5 SMOOTH NON CAVITARY NIL >20 HU 12000 HIGH 312 C/S + TTNA
LT.UL, PER 3 SMOOTH NON CAVITARY BENIGN <15 HU 4200 HIGH 102 TTNA
RT.UL, PER 4.5 SMOOTH NON CAVITARY BENIGN >20 HU 5800
MODER
ATE 136
SPUTUM 
AFB + NIL
LT.UL, PER 4.5 SPICULATED NON CAVITARY NIL >20 HU 7600 LOW 122 TTNA/BIOPSY
RT. UL, PER 4 SMOOTH NON CAVITARY NIL <15HU 7500 HIGH 130 TTNA
RT.LL, PER 3 SMOOTH >15 NIL >20 HU 8400 LOW 120 TTNA/BIOPSY
RT.ML, CEN 4.5 SPICULATED NON CAVITARY NIL >20 HU 14000 HIGH 125 CER. LN. FNAC/BIOPSY
LT.UL, CEN 5 SMOOTH NON CAVITARY NIL <15HU 6530
MODER
ATE 122 BRONCHOSCOPY BIOPSY
RT.LL, CEN 5 SPICULATED NON CAVITARY NIL >20 HU 12000
MODER
ATE 126 BRONCHOSCOPY BIOPSY
RT.LL, CEN 4 SMOOTH NON CAVITARY NIL <15HU 7000
MODER
ATE 238 BRONCHOSCOPY LAVAGE
LT.LL, PER 1.8 SMOOTH NON CAVITARY NIL <15HU 9400
MODER
ATE 130 TTNA/BIOPSY
LT.LL, PER 3.5 SMOOTH NON CAVITARY NIL >20 HU 8600 LOW 100 TTNA/BIOPSY
RT.UL, PER 4 SMOOTH  4-15 NIL <15HU 7520 HIGH 134 CER. LN.FNAC/BIOPSY
RT.UL, CEN 4.2 SMOOTH NON CAVITARY NIL <15HU 6680 HIGH 107 BRONCHOSCOPY LAVAGE
